LIVIVO - Search results -

Search results

Result 1 - 8 of total 8

Search options

Article ; Online: Decreasing Readmission Rates in Patients With Immune-Mediated Toxicities Using an APRN-Led Discharge Teaching Program.

Rohlfs, Michelle L

2022 Volume 26, Issue 6, Page(s) 659–663

Abstract: Patients with cancer are at increased risk for readmission, which can be associated with increased healthcare costs and poor patient outcomes, because of the nature of the disease, treatment complexity, and symptom management. ...

Abstract	Patients with cancer are at increased risk for readmission, which can be associated with increased healthcare costs and poor patient outcomes, because of the nature of the disease, treatment complexity, and symptom management.
MeSH term(s)	Humans ; Patient Discharge ; Patient Readmission ; Advanced Practice Nursing ; Health Care Costs
Language	English
Publishing date	2022-11-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	2014665-6
ISSN	1538-067X ; 1092-1095
ISSN (online)	1538-067X
ISSN	1092-1095
DOI	10.1188/22.CJON.659-663
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5229: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 390: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

Glitza Oliva, Isabella C / Ferguson, Sherise D / Bassett, Roland / Foster, Alexandra P / John, Ida / Hennegan, Tarin D / Rohlfs, Michelle / Richard, Jessie / Iqbal, Masood / Dett, Tina / Lacey, Carol / Jackson, Natalie / Rodgers, Theresa / Phillips, Suzanne / Duncan, Sheila / Haydu, Lauren / Lin, Ruitao / Amaria, Rodabe N / Wong, Michael K /

Diab, Adi / Yee, Cassian / Patel, Sapna P / McQuade, Jennifer L / Fischer, Grant M / McCutcheon, Ian E / O'Brien, Barbara J / Tummala, Sudhakar / Debnam, Matthew / Guha-Thakurta, Nandita / Wargo, Jennifer A / Carapeto, Fernando C L / Hudgens, Courtney W / Huse, Jason T / Tetzlaff, Michael T / Burton, Elizabeth M / Tawbi, Hussein A / Davies, Michael A

Nature medicine

2024

Language	English
Publishing date	2024-04-22
Publishing country	United States
Document type	Published Erratum
ZDB-ID	1220066-9
ISSN	1546-170X ; 1078-8956
ISSN (online)	1546-170X
ISSN	1078-8956
DOI	10.1038/s41591-024-02998-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4212: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 39: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: a case report.

Kim, Dae Won / Barcena, Edelyn / Mehta, Urvi N / Rohlfs, Michelle L / Kumar, Ashok J / Penas-Prado, Marta / Kim, Kevin B

BMC cancer

2015 Volume 15, Page(s) 400

Abstract: Background: Leptomeningeal metastasis of melanoma is a devastating complication with a grave prognosis, and there are no known effective standard treatments. Although selective BRAF inhibitors have demonstrated a significant clinical activity in ... ...

Abstract	Background: Leptomeningeal metastasis of melanoma is a devastating complication with a grave prognosis, and there are no known effective standard treatments. Although selective BRAF inhibitors have demonstrated a significant clinical activity in patients with metastatic melanoma harboring a BRAF mutation, the clinical benefit of BRAF inhibitor-based therapy in leptomeningeal disease is not clear. Case presentation: We present a case of prolonged survival of a patient with BRAF V600E-mutant leptomeningeal disease who was treated with vemurafenib followed by whole brain radiation and a combination of dabrafenib and trametinib. Both vemurafenib and the sequential treatment of radiation and dabrafenib/trametinib led to regression of the leptomeningeal disease, and the patient survived for 19 months after the diagnosis of the leptomeningeal disease. Conclusion: This case suggests a possible clinically meaningful benefit of BRAF inhibitor-based therapy and a need for close investigation of this therapeutic approach in patients with this devastating disease.
MeSH term(s)	Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Magnetic Resonance Imaging ; Male ; Melanoma/diagnosis ; Melanoma/genetics ; Melanoma/metabolism ; Melanoma/pathology ; Meningeal Neoplasms/diagnosis ; Meningeal Neoplasms/drug therapy ; Meningeal Neoplasms/mortality ; Meningeal Neoplasms/secondary ; Middle Aged ; Mutation ; Protein Kinase Inhibitors/administration & dosage ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Proto-Oncogene Proteins B-raf/genetics ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Protein Kinase Inhibitors ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
Language	English
Publishing date	2015-05-13
Publishing country	England
Document type	Case Reports ; Journal Article
ISSN	1471-2407
ISSN (online)	1471-2407
DOI	10.1186/s12885-015-1391-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Full text

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- Full text online
- Order with fees

Article ; Online: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.

Nature medicine

2023 Volume 29, Issue 4, Page(s) 898–905

Abstract: There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in ... ...

Abstract	There is a critical need for effective treatments for leptomeningeal disease (LMD). Here, we report the interim analysis results of an ongoing single-arm, first-in-human phase 1/1b study of concurrent intrathecal (IT) and intravenous (IV) nivolumab in patients with melanoma and LMD. The primary endpoints are determination of safety and the recommended IT nivolumab dose. The secondary endpoint is overall survival (OS). Patients are treated with IT nivolumab alone in cycle 1 and IV nivolumab is included in subsequent cycles. We treated 25 patients with metastatic melanoma using 5, 10, 20 and 50 mg of IT nivolumab. There were no dose-limiting toxicities at any dose level. The recommended IT dose of nivolumab is 50 mg (with IV nivolumab 240 mg) every 2 weeks. Median OS was 4.9 months, with 44% and 26% OS rates at 26 and 52 weeks, respectively. These initial results suggest that concurrent IT and IV nivolumab is safe and feasible with potential efficacy in patients with melanoma LMD, including in patients who had previously received anti-PD1 therapy. Accrual to the study continues, including in patients with lung cancer. ClinicalTrials.gov registration: NCT03025256 .
MeSH term(s)	Humans ; Nivolumab ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Melanoma/pathology ; Lung Neoplasms/drug therapy ; Treatment Outcome ; Ipilimumab
Chemical Substances	Nivolumab (31YO63LBSN) ; Ipilimumab
Language	English
Publishing date	2023-03-30
Publishing country	United States
Document type	Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1220066-9
ISSN	1546-170X ; 1078-8956
ISSN (online)	1546-170X
ISSN	1078-8956
DOI	10.1038/s41591-022-02170-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4212: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 39: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

Glitza, Isabella C / Rohlfs, Michelle / Guha-Thakurta, Nandita / Bassett, Roland L / Bernatchez, Chantale / Diab, Adi / Woodman, Scott E / Yee, Cassian / Amaria, Rodabe N / Patel, Sapna P / Tawbi, Hussein / Wong, Michael / Hwu, Wen-Jen / Hwu, Patrick / Heimberger, Amy / McCutcheon, Ian E / Papadopoulos, Nicholas / Davies, Michael A

ESMO open

2018 Volume 3, Issue 1, Page(s) e000283

Abstract: Objectives: Metastatic melanoma patients with leptomeningeal disease (LMD) have an extremely poor prognosis, with a median survival measured in weeks, and few treatment options. Outcomes of a retrospective cohort of patients with LMD that were treated ... ...

Abstract	Objectives: Metastatic melanoma patients with leptomeningeal disease (LMD) have an extremely poor prognosis, with a median survival measured in weeks, and few treatment options. Outcomes of a retrospective cohort of patients with LMD that were treated with intrathecal interleukin-2 (IT IL-2) were reviewed to assess the long-term efficacy of this therapy. Methods: The records of metastatic melanoma patients with LMD who were treated with IT IL-2 from 2006 to 2014 in a Compassionate Investigational New Drug study were reviewed. IL-2 (1.2 mIU) was administered intrathecally via Ommaya reservoir up to five times per week in the inpatient setting for 4 weeks; patients with good tolerance and clinical benefit received maintenance IT IL-2 every 1-3 months thereafter. Results: The cohort included 43 patients. The median age of the patients was 47 years (range 18-71), and 32 (74%) were male. 23 patients (53%) had positive cerebrospinal fluid (CSF) cytology and radiographic evidence of LMD, 8 (19%) had positive CSF cytology only, 9 (21%) had radiographic evidence only and 3 (7%) were diagnosed based on pathology review after craniotomy. The median overall survival (OS) from initiation of IT IL-2 was 7.8 months (range, 0.4-90.8 months), with 1-year, 2-year and 5-year OS rates of 36%, 26% and 13%. The presence of neurological symptoms (HR 2.1, P=0.03), positive baseline CSF cytology (HR 4.1, P=0.001) and concomitant use of targeted therapy (HR 3.0, P=0.02) was associated with shorter OS on univariate analysis. All patients developed symptoms due to increased intracranial pressure which was managed with supportive medications and/or CSF removal, and there were no treatment-related deaths. Conclusion: These results demonstrate that despite their historically dismal prognosis a subset of metastatic melanoma patients with LMD treated with IT IL-2 can achieve long-term survival, but these data need to be verified in a prospective trial setting.
Language	English
Publishing date	2018-01-24
Publishing country	England
Document type	Journal Article
ISSN	2059-7029
ISSN	2059-7029
DOI	10.1136/esmoopen-2017-000283
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?

Bedikian, Agop Y / Johnson, Marcella M / Warneke, Carla L / Papadopoulos, Nicholas E / Kim, Kevin B / Hwu, Wen-Jen / McIntyre, Susan / Rohlfs, Michelle / Homsi, Jade / Hwu, Patrick

Melanoma research

2011 Volume 21, Issue 1, Page(s) 84–90

Abstract: The aim of this study was to determine the impact of complete response (CR) to systemic therapy on survival. We reviewed the cases of 647 chemo-naive patients with metastatic melanoma who were treated with cisplatin-vinblastine-dacarbazine or cisplatin- ... ...

Abstract	The aim of this study was to determine the impact of complete response (CR) to systemic therapy on survival. We reviewed the cases of 647 chemo-naive patients with metastatic melanoma who were treated with cisplatin-vinblastine-dacarbazine or cisplatin-taxol-dacarbazine alone, or cisplatin-vinblastine-dacarbazine together with interferon α or interleukin-2 plus interferon α. After excluding patients with uveal melanoma and patients who had resection of metastases, 567 patients were eligible to participate in this analysis. An event chart is presented for the 51 patients with CR and for three random samples of patients without CR. We compared overall survival of responders versus nonresponders using response as a time-dependent covariate in a Cox proportional hazards model. In addition, we used the landmark method, choosing 6 months as the landmark. Logistic regression techniques were used to determine factors associated with CR to therapy. All P values were 2-tailed and considered significant at α less than 0.05. Analyses were conducted using SAS for Windows. In this analysis, CR was associated with patients who were younger, male, and who had better performance status, lower M-stage, no liver metastases, and no visceral sites involved, normal LDH and had received biochemotherapy. While accounting for these factors, the relationship between CR and survival remained statistically significant, suggesting a causal relationship between response and survival. Using 6-month landmark analysis method, we still find a significant difference in overall survival between response groups, favoring patients who achieved CR with systemic therapy. In conclusion, CR to systemic therapy is associated with long-term survival in patients with stage IV melanoma.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin/therapeutic use ; Combined Modality Therapy/methods ; Dacarbazine/therapeutic use ; Female ; Humans ; Interferon-alpha/therapeutic use ; Interleukin-2/therapeutic use ; Logistic Models ; Male ; Melanoma/drug therapy ; Melanoma/mortality ; Neoplasm Metastasis ; Paclitaxel/therapeutic use ; Proportional Hazards Models ; Remission Induction ; Sex Factors ; Skin Neoplasms/drug therapy ; Skin Neoplasms/mortality ; Treatment Outcome ; Vinblastine/therapeutic use
Chemical Substances	Interferon-alpha ; Interleukin-2 ; Vinblastine (5V9KLZ54CY) ; Dacarbazine (7GR28W0FJI) ; Paclitaxel (P88XT4IS4D) ; Cisplatin (Q20Q21Q62J)
Language	English
Publishing date	2011-02
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1095779-0
ISSN	1473-5636 ; 0960-8931
ISSN (online)	1473-5636
ISSN	0960-8931
DOI	10.1097/CMR.0b013e328341445f
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3378: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Jakob, John A / Bassett, Roland L / Ng, Chaan S / Curry, Jonathan L / Joseph, Richard W / Alvarado, Gladys C / Rohlfs, Michelle L / Richard, Jessie / Gershenwald, Jeffrey E / Kim, Kevin B / Lazar, Alexander J / Hwu, Patrick / Davies, Michael A

Cancer

2011 Volume 118, Issue 16, Page(s) 4014–4023

Abstract: Background: There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS ... ...

Abstract	Background: There is a need for improved prognostic markers in melanoma. In this study, the authors tested the prognostic significance and clinicopathologic correlations of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) mutations in patients with metastatic melanoma. Methods: Clinical and pathologic data were collected retrospectively on melanoma patients who were clinically tested for BRAF (exon 15) and NRAS (exons 1 and 2) mutations at The University of Texas M. D. Anderson Cancer Center. Analyses were performed to identify significant associations of mutations with tumor and patient characteristics and with survival from the diagnosis of stage IV disease. Results: The genotypes of the full cohort (n = 677) were 47% BRAF mutation, 20% NRAS mutation, and 32% wild-type for BRAF and NRAS ("WT"). Tumor mutation status was associated (P = .008) with the risk of central nervous system involvement at the diagnosis of stage IV disease, with a higher prevalence observed in BRAF-mutant (24%) and NRAS-mutant (23%) patients than in WT patients (12%). Among patients with nonuveal melanoma who underwent mutation testing within 6 months of stage IV diagnosis (n = 313), patients with NRAS mutations had a median survival of 8.2 months from stage IV diagnosis, which was shorter than the median survival of WT patients (15.1 months; P = .004). Multivariate analysis of this population incorporating age, sex, metastases (M1) category, serum lactate dehydrogenase level, and mutation status confirmed that NRAS mutations are associated independently with decreased overall survival (vs WT; P = .005; hazard ratio, 2.05). Conclusions: Patients with BRAF or NRAS mutations were more likely than WT patients to have central nervous system involvement at the time they were diagnosed with distant metastatic disease. NRAS mutation status was identified as an independent predictor of shorter survival after a diagnosis of stage IV melanoma.
MeSH term(s)	Female ; Gene Frequency ; Genes, ras ; Humans ; Melanoma/genetics ; Melanoma/mortality ; Melanoma/pathology ; Melanoma/secondary ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Prognosis ; Proto-Oncogene Proteins B-raf/genetics ; Skin Neoplasms/genetics ; Skin Neoplasms/mortality ; Skin Neoplasms/pathology
Chemical Substances	BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
Language	English
Publishing date	2011-12-16
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1429-1
ISSN	1097-0142 ; 0008-543X ; 1934-662X
ISSN (online)	1097-0142
ISSN	0008-543X ; 1934-662X
DOI	10.1002/cncr.26724
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.146: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report.

Glitza, Isabella C / Haymaker, Cara / Bernatchez, Chantale / Vence, Luis / Rohlfs, Michelle / Richard, Jessie / Lacey, Carol / Mansaray, Rahmatu / Fulbright, Orenthial J / Ramachandran, Renjith / Toth, Christopher / Wardell, Seth / Patel, Sapna P / Woodman, Scott E / Hwu, Wen-Jen / Radvanyi, Laszlo G / Davies, Michael A / Papadopoulos, Nicholas E / Hwu, Patrick

Cancer immunology research

2015 Volume 3, Issue 11, Page(s) 1201–1206

Abstract: Unlabelled: Patients with leptomeningeal disease (LMD) from melanoma have very poor outcomes and few treatment options. We present a case of intrathecal (i.t.) administration of autologous tumor-infiltrating lymphocytes (TIL) in a patient with LMD from ... ...

Abstract	Unlabelled: Patients with leptomeningeal disease (LMD) from melanoma have very poor outcomes and few treatment options. We present a case of intrathecal (i.t.) administration of autologous tumor-infiltrating lymphocytes (TIL) in a patient with LMD from metastatic melanoma. The patient developed LMD after previous treatments with surgery, high-dose bolus interleukin-2 (HD IL2), and systemic TIL infusion and experienced radiographic progression after intrathecal IL2 (i.t. IL2) therapy. The patient received weekly treatment with increasing numbers of i.t. TIL followed by twice-weekly i.t. IL2. The patient received three i.t. TIL infusions and did not experience any toxicities beyond those expected with i.t. IL2 therapy. Analysis of cerebrospinal fluid demonstrated increased inflammatory cytokines following the i.t. Treatments: Subsequent imaging demonstrated disease stabilization, and neurological deficits also remained stable. The patient expired 5 months after the initiation of i.t. TIL therapy with disease progression in the brain, liver, lung, and peritoneal and retroperitoneal lymph nodes, but without LMD progression. These results demonstrate the safety of i.t. administration of TIL in melanoma patients with LMD and support the feasibility of conducting a prospective clinical trial to determine this therapy's clinical benefit among these patients.
MeSH term(s)	Cytokines/cerebrospinal fluid ; Disease Progression ; Fatal Outcome ; Humans ; Injections, Spinal ; Lymphocytes, Tumor-Infiltrating/transplantation ; Male ; Melanoma/secondary ; Melanoma/therapy ; Meningeal Carcinomatosis/therapy ; Middle Aged
Chemical Substances	Cytokines
Language	English
Publishing date	2015-11
Publishing country	United States
Document type	Case Reports ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2732489-8
ISSN	2326-6074 ; 2326-6066
ISSN (online)	2326-6074
ISSN	2326-6066
DOI	10.1158/2326-6066.CIR-15-0071
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7022: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Your last searches

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito